Committee adopts amendment and advances compounding-clarity bill after wide testimony

Sponsors described House Bill 1262 as a statutory clarification to align Colorado law with federal compounding frameworks and preserve patient access to compounded medications. Senator Ball said the measure is intended to preserve the status quo and head off litigation that might treat compounding pharmacies like manufacturers.

A broad coalition of compounding pharmacists, hospital pharmacy leaders and health systems told the committee that compounding is essential to pediatric care, individualized dosing, and emergency responses to shortages. Kristen Youngdahl, a compounding pharmacist, said compounding supports women’s health and other tailored therapies; Lee Rosebush of the Outsourcing Facility Association and Mark Spiecker (StackPharma) described how outsourcing facilities support hospitals during shortages. Testimony emphasized that 503A compounding pharmacies and 503B outsourcing facilities serve distinct clinical roles.

Eli Lilly’s Zoe Powers testified in opposition, saying the bill would limit the Colorado Board of Pharmacy’s rulemaking authority and could prevent the state from acting independently in emerging safety situations; she cited Colorado’s past actions in the New England Compounding Center case as an example of state-level intervention. "The bill would strip the Colorado Board of Pharmacy of its core authority," Powers said, and warned that adopting a nonbinding FDA draft guidance in statute could make Colorado an outlier.

Sponsors and committee members responded by offering a friendly amendment, L7, that exempts 503B outsourcing facilities from the bill’s scope, narrowing the measure to focus on 503A compounding pharmacies. The committee adopted amendment L7 by consent. After further discussion the sponsor moved HB1262, as amended, to the Committee of the Whole with a favorable recommendation; the committee then placed the bill on the consent calendar.